Pfizer Inc. (NYSE: PFE) agreed to buy Anacor Pharmaceuticals Inc. (Nasdaq: ANAC) for $5.2 billion, gaining control of an experimental treatment for the skin condition known as eczema in its first deal since walking away from a $160 billion takeover of Allergan Plc.

Pfizer will pay $99.25 in cash for each Anacor share, the companies said in a statement on Monday. The transaction, which represents about a 55 percent premium on Friday’s closing price, is scheduled to be completed in the third quarter, and may start adding to Pfizer’s earnings in 2018.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.